Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/1017
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorSAFADI, Marco Aurelio Palazzi-
dc.contributor.authorBEREZIN, Eitan Naaman-
dc.contributor.authorOSELKA, Gabriel Wolf-
dc.date.accessioned2013-07-30T15:18:21Z-
dc.date.available2013-07-30T15:18:21Z-
dc.date.issued2012-
dc.identifier.citationJORNAL DE PEDIATRIA, v.88, n.3, p.195-202, 2012-
dc.identifier.issn0021-7557-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1017-
dc.description.abstractObjectives: To assess the epidemiology of meningococcal disease (MD) in Brazil and the impact that recent evidence and lessons learned from the introduction of meningococcal C conjugate (MCC) vaccines into immunization programs may have on different strategies of vaccine use. Sources: Non-systematic review of the MEDLINE, SciELO and LILACS databases covering the period from 2000 to 2011. Summary of the findings: Meningococcal disease is endemic in Brazil, with periodic occurrence of outbreaks. Most cases are associated with serogroup C and the highest incidence rates are observed in infants, encouraging the introduction of MCC vaccine in the National Immunization Program in 2010 for children under 2 years old. The introduction of MCC vaccines into immunization programs in Europe, Canada and Australia proved to be effective, with dramatic reduction in the incidence of serogroup C meningococcal disease, not only in the vaccinated, but also in the unvaccinated individuals. Long-term effectiveness of MCC vaccines was dependent on a combination of antibody persistence, immunologic memory and herd protection. Recent evidence indicating that antibody persistence is not long-lasting in young immunized children, and that immunologic memory is not fast enough to protect them against the disease, emphasize the importance of herd protection to maintain the population protected. Conclusions: The rapid decline of antibody titers in children vaccinated in the first years of life suggests the need to incorporate booster doses before adolescence, especially in locations like Brazil, where the immunization program did not incorporate catch-up campaigns including adolescents, lacking the herd immunity effect.-
dc.description.abstractObjetivos: Analisar a epidemiologia da doença meningocócica no Brasil e o impacto que as recentes evidências acumuladas com a incorporação das vacinas meningocócicas C conjugadas nos programas de imunização podem ter nas diferentes estratégias de uso dessas vacinas. Fontes dos dados: Revisão nas bases de dados MEDLINE, SciELO e LILACS no período de 2000 a 2011. Síntese dos dados: No Brasil, a doença meningocócica é endêmica, com ocorrência periódica de surtos. Os maiores coeficientes de incidência ocorrem em lactentes, sendo o sorogrupo C responsável pela maioria dos casos, motivando a introdução da vacina meningocócica C conjugada no Programa Nacional de Imunizações, em 2010, para crianças menores de 2 anos. A introdução das vacinas meningocócicas C conjugadas nos programas de imunização na Europa, Canadá e Austrália mostrou-se efetiva, com dramática redução na incidência de doença causada pelo sorogrupo C, não apenas nos vacinados, mas também em não vacinados. A efetividade em longo prazo dessas vacinas mostrou-se dependente de uma combinação de persistência de anticorpos, memória imunológica e proteção indireta. Recentes evidências indicando que a persistência de anticorpos não é duradoura em crianças pequenas imunizadas e que a memória imunológica não é rápida o suficiente para protegê-las contra a doença enfatizam a importância da proteção indireta para manutenção da população protegida. Conclusões: A rápida queda de títulos de anticorpos em crianças vacinadas nos primeiros anos de vida sugere a necessidade de incorporarmos doses de reforço antes da adolescência, especialmente em locais como o Brasil, onde ainda não contamos com o efeito da proteção indireta da população.-
dc.language.isoeng-
dc.language.isopor-
dc.publisherSOC BRASIL PEDIATRIA-
dc.relation.ispartofJornal de Pediatria-
dc.rightsopenAccess-
dc.subjectmeningococcal disease-
dc.subjectconjugate meningococcal vaccines-
dc.subjectdoença meningocócica-
dc.subjectvacinas meningocócicas conjugadas-
dc.subject.otherunited-kingdom-
dc.subject.otherimmunization campaign-
dc.subject.otherherd-immunity-
dc.subject.otherc disease-
dc.subject.othervaccination-
dc.subject.otherimpact-
dc.subject.otherbrazil-
dc.subject.othercarriage-
dc.subject.otherspain-
dc.subject.otheruk-
dc.subject.otherNeisseria meningitidis-
dc.titleA critical appraisal of the recommendations for the use of meningococcal conjugate vaccines-
dc.title.alternativeAnálise crítica das recomendações do uso das vacinas meningocócicas conjugadas-
dc.typearticle-
dc.rights.holderCopyright SOC BRASIL PEDIATRIA-
dc.identifier.doi10.2223/JPED.2167-
dc.identifier.pmid22622596-
dc.subject.wosPediatrics-
dc.type.categoryreview-
dc.type.versionpublishedVersion-
hcfmusp.author.externalSAFADI, Marco Aurelio Palazzi:FCMSCSP, Dept Pediat, Sao Paulo, Brazil-
hcfmusp.author.externalBEREZIN, Eitan Naaman:FCMSCSP, Dept Pediat, Sao Paulo, Brazil-
hcfmusp.description.beginpage195-
hcfmusp.description.endpage202-
hcfmusp.description.issue3-
hcfmusp.description.volume88-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000306229300003-
hcfmusp.origem.id2-s2.0-84864317173-
hcfmusp.origem.idSCIELO:S0021-75572012000300003-
hcfmusp.publisher.cityRIO DE JANEIRO, RJ-
hcfmusp.publisher.countryBRAZIL-
hcfmusp.relation.referenceAuckland C, 2006, J INFECT DIS, V194, P1745, DOI 10.1086/509619-
hcfmusp.relation.referenceBalmer P, 2002, J MED MICROBIOL, V51, P717-
hcfmusp.relation.referenceBarroso DE, 2007, MEM I OSWALDO CRUZ, V102, P773, DOI 10.1590/S0074-02762007005000104-
hcfmusp.relation.referenceBilukha Oleg O., 2005, Morbidity and Mortality Weekly Report, V54, P1-
hcfmusp.relation.referenceBrasil. Ministerio da Saude, 2005, GUIA VIG EP, P541-
hcfmusp.relation.referenceCampbell H, 2010, CLIN VACCINE IMMUNOL, V17, P840, DOI 10.1128/CVI.00529-09-
hcfmusp.relation.referenceCano R, 2004, Euro Surveill, V9, P11-
hcfmusp.relation.referenceCenters for Disease Control and Prevention, 2011, MMWR-MORBID MORTAL W, V60, P72-
hcfmusp.relation.referenceCohn AC, 2010, CLIN INFECT DIS, V50, P184, DOI 10.1086/649209-
hcfmusp.relation.referenceDanzig Lisa, 2004, Pediatr Infect Dis J, V23, pS285-
hcfmusp.relation.referencede Voer RM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012144-
hcfmusp.relation.referencede Greeff SC, 2006, PEDIATR INFECT DIS J, V25, P79, DOI 10.1097/01.inf.0000195594.41449.c6-
hcfmusp.relation.referencede Lemos APS, 2007, J CLIN MICROBIOL, V45, P1266, DOI 10.1128/JCM.02510-06-
hcfmusp.relation.referencede Voer RM, 2009, CLIN VACCINE IMMUNOL, V16, P1521, DOI 10.1128/CVI.00274-09-
hcfmusp.relation.referenceDe Wals P, 2004, JAMA-J AM MED ASSOC, V292, P2491, DOI 10.1001/jama.292.20.2491-
hcfmusp.relation.referenceDe Wals P, 2011, PEDIATR INFECT DIS J, V30, P566, DOI 10.1097/INF.0b013e31820e8638-
hcfmusp.relation.referenceGOLDSCHN.I, 1969, J EXP MED, V129, P1327, DOI 10.1084/jem.129.6.1327-
hcfmusp.relation.referenceGranoff DM, 2008, VACCINES, P399-
hcfmusp.relation.referenceHankins J, 2010, J PEDIAT-BRAZIL, V86, P256, DOI 10.2223/JPED.2021-
hcfmusp.relation.referenceHarrison LH, 2009, VACCINE, V27, pB51, DOI 10.1016/j.vaccine.2009.04.063-
hcfmusp.relation.referenceIser BPM, 2012, EPIDEMIOL INFECT, V140, P906, DOI 10.1017/S0950268811001610-
hcfmusp.relation.referenceKafetzis DA, 2007, CLIN MICROBIOL INFEC, V13, P550, DOI 10.1111/j.1469-0691.2007.01704.x-
hcfmusp.relation.referenceLarrauri A, 2005, VACCINE, V23, P4097, DOI 10.1016/j.vaccine.2005.03.045-
hcfmusp.relation.referenceLemos APS, 2010, J INFECTION, V60, P209, DOI 10.1016/j.jinf.2009.11.014-
hcfmusp.relation.referenceMaiden MCJ, 2002, LANCET, V359, P1829, DOI 10.1016/S0140-6736(02)08679-8-
hcfmusp.relation.referenceMiller E, 2001, VACCINE, V20, pS58, DOI 10.1016/S0264-410X(01)00299-7-
hcfmusp.relation.referenceNational Advisory Committee on Immunization (NACI), 2009, CAN COMMUN DIS REP, V35, P1-
hcfmusp.relation.referencePan American Health Organization, 2007, CDCPAHODPCCDA482 PAN, P2-
hcfmusp.relation.referencePerrett KP, 2010, CLIN INFECT DIS, V50, P1601, DOI 10.1086/652765-
hcfmusp.relation.referencePickering LK, 2009, RED BOOK 2009 REP CO, P455-
hcfmusp.relation.referencePollard AJ, 2003, LANCET INFECT DIS, V3, P68, DOI 10.1016/S1473-3099(03)00511-5-
hcfmusp.relation.referenceRamsay ME, 2003, BRIT MED J, V326, P365, DOI 10.1136/bmj.326.7385.365-
hcfmusp.relation.referenceSacchi CT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020675-
hcfmusp.relation.referenceSafadi Marco Aurelio Palazzi, 2006, J Pediatr (Rio J), V82, pS35-
hcfmusp.relation.referenceSafadi MAP, 2010, NEUROL RES, V32, P263, DOI 10.1179/016164110X12644252260754-
hcfmusp.relation.referenceSalleras L, 2003, VACCINE, V21, P725, DOI 10.1016/S0264-410X(02)00589-3-
hcfmusp.relation.referenceSao Paulo. Secretaria de Saude do Estado de Sao Paulo, RESP TRANSM DIS-
hcfmusp.relation.referenceSnape MD, 2008, BRIT MED J, V336, P1487, DOI 10.1136/bmj.39563.545255.AE-
hcfmusp.relation.referenceStephens DS, 1999, LANCET, V353, P941, DOI 10.1016/S0140-6736(98)00279-7-
hcfmusp.relation.referenceTrotter CL, 2004, LANCET, V364, P365, DOI 10.1016/S0140-6736(04)16725-1-
hcfmusp.relation.referenceTrotter CL, 2007, FEMS MICROBIOL REV, V31, P101, DOI 10.1111/j.1574-6976.2006.00053.x-
hcfmusp.relation.referenceTrotter CL, 2009, EXPERT REV VACCINES, V8, P851, DOI [10.1586/erv.09.48, 10.1586/ERV.09.48]-
hcfmusp.relation.referenceUnited Kingdom Department of Health, 2006, PLANN CHANG ROUT CHI-
hcfmusp.relation.referenceWeidlich L, 2008, J INFECTION, V57, P324, DOI 10.1016/j.jinf.2008.07.014-
hcfmusp.relation.reference[Anonymous], 2002, WKLY EPIDEMIOL REC, V77, P331-
dc.description.indexMEDLINE-
hcfmusp.citation.scopus16-
hcfmusp.scopus.lastupdate2022-07-08-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MPE
Departamento de Pediatria - FM/MPE

Artigos e Materiais de Revistas Científicas - HC/ICr
Instituto da Criança - HC/ICr


Files in This Item:
File Description SizeFormat 
art_OSELKA_A_critical_appraisal_of_the_recommendations_for_the_2012_eng.PDFpublishedVersion (English)301.93 kBAdobe PDFThumbnail
View/Open
art_OSELKA_A_critical_appraisal_of_the_recommendations_for_the_2012_por.PDFpublishedVersion (Portuguese)309.68 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.